Category: Uncategorized

The European Health and Digital Executive Agency (HaDEA) has selected a consortium comprising SK bioscience, IDT Biologika, and Vaxxas for... Read more

Doug Ingram, who has led Sarepta Therapeutics for nearly a decade, announced his plans to retire by the end of... Read more

On February 26, 2026, Boehringer Ingelheim secured an exclusive global license for a preclinical small-molecule inhibitor program from Sitryx Therapeutics.... Read more

Novartis has unveiled plans to construct a new radioligand therapy (RLT) manufacturing facility in Denton, Texas. This project marks a... Read more

Following a year-long strategic review, Viatris announced on February 26, 2026, a plan to reduce its global workforce by approximately... Read more

At the 33rd Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented 96-week data from the Mocha study (IMPAACT... Read more

On February 26, 2026, the FDA granted expanded approval for Boehringer Ingelheim’s Hernexeos (zongertinib) as a first-line treatment for patients... Read more

On February 25, 2026, the U.S. Food and Drug Administration (FDA) issued full approval for Pfizer’s Braftovi (encorafenib) in combination... Read more